BioSpace News Archive

Amgen (NASDAQ:AMGN) today announced new data from its oncology pipeline in lung cancer will be presented during the 2020 World Conference on Lung Cancer (WCLC) hosted by the International Association for the Study of Lung Cancer taking place virtually from Jan. 28-31, 2021.

National survey finds 75% of those managing hypertension would measure heart vitals more often with passive monitoring devices

Medly Pharmacy continues its nationwide expansion providing innovative prescription delivery services to the Raleigh, North Carolina market

Taiho Oncology, Inc. and Servier today announced that data for LONSURF ® (trifluridine and tipiracil) in previously treated patients with metastatic gastric cancer (mGC) and metastatic gastroesophageal junction adenocarcinoma (mGEJC) will be presented during the 2021 American Society of Clinical Oncology Gastrointestinal Cancers

As part of its ongoing commitment to advance transparency and efficiency in precision medicine, Concert Genetics announced the launch of a preferred network of genetic testing laboratories.

New results from the AI-EMERGE® study show Freenome’s multiomics blood test can detect colorectal advanced adenomas at 41% sensitivity and 90% specificity, which is comparable to or better than currently available non-invasive tests for colorectal cancer screening. This data, to be presented at ASCO-GI, build on previously reported data from a separate cohort that showed Freenome’s multiomics blood test can detect early-stage colorectal cancer

- Completion of maralixibat rolling NDA targeted for Q1 2021 - Expecting first-patient-in for volixibat studies in ICP and PSC, and maralixibat study in biliary atresia in Q1 2021 - Launching volixibat primary biliary cholangitis program in H2 2021 - European commercial leader hired in anticipation of potential approval of maralixibat

Relievant Medsystems, a privately-held medical device company transforming the treatment of Chronic Low Back Pain, announced the launch of Intracept.com – a new website helping educate patients regarding the Intracept Procedure.

Today, the U.S. Food and Drug Administration released the agency’s first Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD) Action Plan . This action plan describes a multi-pronged approach to advance the Agency’s oversight of AI/ML-based medical software.

Company to Accelerate Mass Manufacturing and Commercialization of Proprietary PCR-Free Multi-Omics Technology Following Year of Rapid Growth